Kovid-19 - Huvemek® Phase 2 clinical trial
Press Release (Preprint)
, Kovid-19 - Huvemek® Phase 2 clinical trial, Press Release (Preprint)
Phase 2 results from a multicenter RCT of hospitalized patients in Bulgaria showing faster viral clearance, greater clinical improvement, and improved biomarkers with treatment. Ivermectin was taken on an empty stomach, potentially reducing lung tissue concentration by ~2.5x [twitter.com]. Limited data has been reported currently. No serious adverse events were observed. EudraCT 2020-002091-12.
|
risk of no improvement, 31.6% lower, RR 0.68, p = 0.28, treatment 13 of 50 (26.0%), control 19 of 50 (38.0%), NNT 8.3, day 7, patients with improvement on WHO scale.
|
|
risk of no improvement, 34.5% lower, RR 0.66, p = 0.07, treatment 19 of 50 (38.0%), control 29 of 50 (58.0%), NNT 5.0, day 4, patients with improvement on WHO scale.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Huvemek et al., 25 Mar 2021, Double Blind Randomized Controlled Trial, Bulgaria, preprint, 1 author, average treatment delay 7.0 days, dosage 400μg/kg days 1-3.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.